Active — Not RecruitingNot Applicable

Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Brazil5,354 participantsStarted 2025-09-22

Plain-language summary

This is a cross-sectional serosurvey using household cluster sampling conducted before the VLA1553 pilot vaccination strategy will be implemented in about 10 municipalities in Brazil.

Who can participate

Age range2 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Individuals residing in the selected municipalities of Brazil where the VLA1553 pilot vaccination strategy will be implemented.
✓. Individuals ≥2 years of age
✓. Individuals who sleep 3 nights a week or more in a household that is selected by cluster sampling.

What they're measuring

To prospectively evaluate the association between vaccination uptake and previous CHIKV exposure (pre-existing immunity to CHIKV infection) after implementing a pilot vaccination in the age-group approved per label.

Timeframe: on Day 1

Trial details

NCT IDNCT07163845

SponsorValneva Austria GmbH

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-07-31

View on ClinicalTrials.gov More Chikungunya Virus Infection trials